新兴数字技术与方法联合激励措施对2型糖尿病患者HbA1c的影响:平行开放随机对照试验的研究方案
本研究为前瞻性随机对照试验,在昆山市第一人民医院于2023年4月1日至2024年12月31日开展,随访3个月,比较三组:A组数字干预+虚拟激励+常规治疗、B组数字干预+实物激励+常规治疗、C组常规治疗,评估HbA1c、自我血糖监测(SMBG)检测率、糖尿病自我效能等指标。
要点
- 三组分别为数字干预+虚拟激励、数字干预+实物激励及常规治疗,随访3个月。
- 主要观察指标包括HbA1c、体重、SMBG检测率、糖尿病自我效能及糖尿病相关医疗费用。
- 试验在中国临床试验注册中心注册,注册号ChiCTR2300070753,注册日期2023年4月22日。
核心结论
- 该试验旨在评估基于行为经济学的数字干预对2型糖尿病患者HbA1c、SMBG检测率、糖尿病自我效能等指标的影响。
- 作者认为该研究具有新颖性和社会价值,因为已发表研究多为基于行为经济学理论的线下干预,针对2型糖尿病患者的线上干预研究很少。
研究设计与样本
- 前瞻性随机对照试验,在昆山市第一人民医院于2023年4月1日至2024年12月31日开展,随访3个月。
- 随机化方法通过EDC临床试验中心的随机化系统建立并实施。
- 三组:A组数字干预+虚拟激励+常规治疗,B组数字干预+实物激励+常规治疗,C组常规治疗。
- 在基线、1个月、2个月和3个月记录HbA1c、体重、SMBG检测率、糖尿病自我效能和糖尿病相关医疗费用。
- 采用Shapiro-Wilk检验进行正态性检验,Pearson相关分析进行相关性分析,脱落者单独分析,采用方差分析或精确概率计算比较人口学数据和其他基线指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a common metabolic disease that requires long-term management and treatment. Digital intervention, as an emerging medical model, has been widely used in the treatment of T2DM patients. Behavioral economics theory provides a favorable perspective for studying the effect of digital intervention because it can reveal the decision-making mechanisms behind human behavior and provide more effective interventions for digital intervention. The purpose of this trial is to evaluate the impact of behaviorally based digital intervention on T2DM patients' HbA1c, self-monitoring of blood glucose (SMBG) testing rate, diabetes self-efficacy, and other indicators compared to conventional treatment. METHODS: This trial is a prospective randomized controlled trial conducted at the First People's Hospital of Kunshan City from April 1, 2023, to December 31, 2024, with a follow-up period of 3 months. The specific randomization method was established and implemented through the EDC clinical trial center's randomization system. We will measure and collect baseline data from three groups, including Group A: digital intervention + virtual incentives + conventional treatment, Group B: digital intervention + physical incentives + conventional treatment, and Group C: conventional treatment. HbA1c, weight, SMBG testing rate, diabetes self-efficacy, and diabetes-related medical expenses will be recorded at baseline, 1 month, 2 months, and 3 months for all three groups. The Shapiro-Wilk test will be used to test for normality, and Pearson correlation analysis will be used for correlation analysis. Dropouts will be analyzed separately. Analysis of variance or exact probability calculation will be used to compare demographic data and other baseline indicators. DISCUSSION: This study is a novel clinical trial that integrates multiple disciplines (economics and medicine) and uses digital technology to deliver the intervention. Most published studies were offline interventions based on behavioral economics theory, but very few were on online interventions for T2DM patients. This study has both novelty and social value. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2300070753. Registered on 2023/04/22.
引用
- Zhong S, Jiang J, Liu H, et al. Effect of emerging digital technologies and methodologies combined with incentives on HbA1c in patients with type 2 diabetes mellitus: study protocol for a parallel, open randomized controlled trial. Trials. 2024. PMID: 38303057. doi:10.1186/s13063-024-07950-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。